Correction of the Gene Defect in Cystic Fibrosis: Is It Too Late for Bone?
作者信息
Tangpricha Vin
机构信息
Division of Endocrinology, Metabolism & Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
出版信息
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2359-e2361. doi: 10.1210/clinem/dgab074.
Abstract
摘要
相似文献
1
Correction of the Gene Defect in Cystic Fibrosis: Is It Too Late for Bone?
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2359-e2361. doi: 10.1210/clinem/dgab074.
2
The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis.
J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1248-e1261. doi: 10.1210/clinem/dgaa890.
3
A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
J Pediatr Health Care. 2019 May-Jun;33(3):356-364. doi: 10.1016/j.pedhc.2018.08.013.
4
Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Am J Respir Crit Care Med. 2018 Jun 1;197(11):1433-1442. doi: 10.1164/rccm.201710-1983OC.
5
Ivacaftor for patients with cystic fibrosis.
Expert Rev Respir Med. 2014 Oct;8(5):533-8. doi: 10.1586/17476348.2014.951333. Epub 2014 Aug 22.
6
Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
J Cyst Fibros. 2017 Jan;16(1):89-90. doi: 10.1016/j.jcf.2016.10.008. Epub 2016 Oct 31.
7
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Ther Adv Respir Dis. 2015 Dec;9(6):313-26. doi: 10.1177/1753465815601934. Epub 2015 Sep 28.
8
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Cochrane Database Syst Rev. 2018 Aug 2;8(8):CD010966. doi: 10.1002/14651858.CD010966.pub2.
9
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
10
Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension.
Nutrition. 2021 May;85:111124. doi: 10.1016/j.nut.2020.111124. Epub 2021 Feb 8.
引用本文的文献
1
Treatment of cystic fibrosis related bone disease.
J Clin Transl Endocrinol. 2021 Dec 21;27:100291. doi: 10.1016/j.jcte.2021.100291. eCollection 2022 Mar.
本文引用的文献
1
Men's health in the modern era of cystic fibrosis.
J Cyst Fibros. 2021 Nov;20(6):e121-e123. doi: 10.1016/j.jcf.2020.12.013. Epub 2020 Dec 26.
2
The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis.
J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1248-e1261. doi: 10.1210/clinem/dgaa890.
3
Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis.
N Engl J Med. 2019 Nov 7;381(19):1863-1865. doi: 10.1056/NEJMe1911602. Epub 2019 Oct 31.
4
Origins of cystic fibrosis lung disease.
N Engl J Med. 2015 Jan 22;372(4):351-62. doi: 10.1056/NEJMra1300109.
5
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
6
Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone.
Thorax. 2007 Jul;62(7):650-1. doi: 10.1136/thx.2006.075887.
Zotero 插件